Gut toxicity during hemopoietic stem cell transplantation may predict acute graft-versus-host disease severity in patients

Digestive Diseases and Sciences

Volumn 52, Issue 9, 2007, Pages 2340-2345

  Johansson, Jan Erik ^a   Ekman, Tor ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Acute graft versus host disease; Allogeneic bone marrow transplantation; Gut toxicity; Intestinal barrier function

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENTEROPATHY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTESTINE FUNCTION; INTESTINE MUCOSA PERMEABILITY; MALE; MYELOABLATIVE CONDITIONING; PRIORITY JOURNAL; TOXICITY; UNSPECIFIED SIDE EFFECT; WHOLE BODY RADIATION;

ACUTE DISEASE; ADULT; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINES; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 34547830319     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-006-9404-x     Document Type: Article

References (22)

1. Fegan C, Poynton CH, Whittaker JA (1990) The gut mucosal barrier in bone marrow transplantation. Bone Marrow Transplant 5(6):373-377
2. Johansson JE, Ekman T (1997) Gastrointestinal toxicity related to bone marrow transplantation: disruption of the intestinal barrier precedes clinical findings. Bone Marrow Transplant 19(9):921-925
3. Berg R (1983) Bacterial translocation from the gastrointestinal tract of mice receiving immunosuppressive chemotherapeutic agents. Curr Microbiol 8:285-292
4. Przepiorka D, Weisdorf D, Martin P, et al. (1995) 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transpl 15(6):825-828
5. Holler E, Kolb HJ, Mittermuller J, et al. (1995) Modulation of acute graft-versus-host disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF alpha) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F). Blood 86(3):890-899
6. Holler E, Kolb HJ, Moller A, et al. (1990) Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 75(4):1011-1016 [see comments]
7. Antin JH, Weinstein HJ, Guinan EC, et al. (1994) Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood 84(4):1342-1348
8. Xun CQ, Thompson JS, Jennings CD, Brown SA, Widmer MB (1994) Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2- incompatible transplanted SCID mice. Blood 83(8):2360-2367
9. Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL (1997) Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 90(8):3204-3213
10. Hill GR, Teshima T, Gerbitz A, et al. (1999) Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia. J Clin Invest 104(4):459-467
11. Nestel FP, Price KS, Seemayer TA, Lapp WS (1992) Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. J Exp Med 175(2):405-413
12. Storb R, Prentice RL, Buckner CD, et al. (1983) Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. N Engl J Med 308(6):302-307
13. Panoskaltsis-Mortari A, Lacey DL, Vallera DA, Blazar BR (1998) Keratinocyte growth factor administered before conditioning ameliorates graft-versus-host disease after allogeneic bone marrow transplantation in mice. Blood 92(10):3960-3967
14. Hill GR, Cooke KR, Teshima T, et al. (1998) Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation. J Clin Invest 102(1):115-123
15. Slavin S, Nagler A, Naparstek E, et al. (1998) Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91(3):756-763
16. Adkins D, Brown R, Khoury H, et al. (1998) Low-intensity conditioning regimen for related donor allogeneic peripheral blood stem cell (PBSC) transplant using low-dose (550 cGy) high dose rate (30 cGy/min) single-exposure total body irradiation (TBI). Blood 92(10):138a
17. Johansson JE, Brune M, Ekman T (2001) The gut mucosa barrier is preserved during allogeneic, hemopoietic stem cell transplantation with reduced intensity conditioning. Bone Marrow Transpl 28(8):737-742
18. Bjarnason I, O'Morain C, Levi AJ, Peters TJ (1983) Absorption of 51-chromium-labeled ethylenediaminetetraacetate in inflammatory bowel disease. Gastroenterology 85(2):318-322
19. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47(1):207-214
20. Lehnert S, Rybka WB, Seemayer TA (1986) Amplification of the graft-versus-host reaction by partial body irradiation. Transplantation 41(6):675-679
21. Lehnert S, Rybka WB (1994) Amplification of the graft-versus-host reaction by cyclophosphamide: dependence on timing of drug administration. Bone Marrow Transpl 13(4):473-477
22. Sykes M, Eisenthal A, Sachs DH (1988) Mechanism of protection from graft-vs-host disease in murine mixed allogeneic chimeras. I. Development of a null cell population suppressive of cell-mediated lympholysis responses and derived from the syngeneic bone marrow component. J Immunol 140(9):2903-2911